NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF

Nanobiotix S.A.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$21.08−0.22 (-1.03%)

Close on Oct 19, 2026

Nanobiotix S.A. cash flow statement

AnnualQuarterlyTTM

EUR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Depreciation & Amortization	1.69	1.75	1.64	1.58	1.84	2.00	1.98	0.73
Stock-Based Compensation	3.99	4.65	3.48	3.34	3.78	3.33	4.84	2.20
Change in Accounts Receivable	0.95	-2.24	-0.87	-0.11	0.07	-0.06	-0.10	0.17
Operating Cash Flow	-38	-21	-13	-39	-35	-31	-46	-31
Capital Expenditures	-0.61	-0.92	-0.35	-0.10	-0.27	-0.11	-1.22	-0.49
Investing Cash Flow	-0.65	-1.03	-0.38	0.15	-0.29	-0.13	-1.63	0.08
Stock Issued	–	–	–	–	–	82	–	–
Debt Issued	48	0	0	0	0	12	16	19
Debt Repaid	-4.00	-3.33	-3.21	-3.83	-3.35	-0.28	-0.56	–
Financing Cash Flow	42	-5.55	51	-5.94	-6.12	127	46	18
Foreign Exchange Rate Adjustments	-0.45	0.10	-0.06	0.09	0.08	-0.07	0.03	0.06
Net Change in Cash	3.40	-28	37	-45	-42	96	-1.24	-13
Free Cash Flow	-38	-22	-14	-39	-36	-31	-47	-31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -33.2%
Net margin: -73.5%
Return on equity, FY2025: –

Financial strength

Current ratio: 1.44
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 129.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.